Last $0.90 USD
Change Today +0.052 / 6.15%
Volume 290.1K
ENZN On Other Exchanges
Symbol
Exchange
Frankfurt
As of 8:10 PM 04/15/14 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

George W. Hebard III, M.B.A

Interim Principal Executive Officer and Interim Chief Operating Officer, Enzon Pharmaceuticals Inc.
AgeTotal Calculated CompensationThis person is connected to 0 board members in 0 different organizations across 2 different industries.

39$652,794
As of Fiscal Year 2012

Background*

Mr. George W. Hebard, III, MBA has been Managing Director of Icahn Capital LP since September 2011. Mr. Hebard serves at Panaco Inc. Mr. Hebard has been an Interim Principal Executive Officer and Chief Operating Officer of Enzon Pharmaceuticals Inc. since May 16, 2012 and served as its Principal Financial Officer from August 9, 2013 to December 31, 2013. He served as the Managing Director of Blue Harbour Group from 2005 to 2011. Prior to Blue Harbour Group, Mr. Hebard ...

Read Full Background

Corporate Headquarters*

20 Kingsbridge Road
Piscataway, New Jersey 08854

United States

Phone: 732-980-4500
Fax: --

Board Members Memberships*

Former Director
2012-2013
Interim Principal Executive Officer and Interim Chief Operating Officer

Education*

MBA
INSEAD
BA
Princeton University

Other Affiliations*

Annual Compensation*

Salary$226,365
Total Annual Compensation$226,365

Stock Options*

Restricted Stock Awards$151,410
All Other Compensation$5,127
Exercisable Options3,432
Unexercisable Options80,365
Unexercisable Options Value$18,375
Total Value of Options$36,750
Total Number of Options164,162

Total Compensation*

Total Annual Cash Compensation$244,772
Total Short Term Compensation$226,365
Other Long Term Compensation$156,537
Total Calculated Compensation$652,794
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ENZN:US $0.90 USD +0.052

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
Michael S. Anderson Chief Executive Officer and Director
Flamel Technologies SA
--
Judith Greciet Ph.D., PharmacyChief Executive Officer, Director and Member of Corporate Development Committee
BioAlliance Pharma
€276.9K
Ian R. Garland Chief Executive Officer, Director and Member of Nominations & Corporate Governance Committee
Vernalis plc
585.0K GBP
Manuel Llobet Chief Executive Officer and Executive Director
Allergy Therapeutics plc
218.0K GBP
Kleanthis G. Xanthopoulos Ph.D.Chief Executive Officer, President, Principal Financial & Accounting Officer and Director
Regulus Therapeutics Inc.
$600.0K
Compensation as of Fiscal Year --.

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ENZON PHARMACEUTICALS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.